





## ANITSCHKOW LECTURE:

Prof. Joseph L. Witztum, USA  
Sunday October 4

## PLENARY PROGRAMME

### Monday October 5

Nature and nurture – impact of traditional risk factors, environment and genes

Global perspectives of cardiovascular disease, and impact of risk factors  
**Gregory Roth, USA**

Can polygenic scores reach clinical practice?  
**Anne Tybjærg-Hansen, Denmark**

What is the environment doing to cardiovascular health?  
**Nicole Probst-Hensch, Switzerland**

Age, the unpreventable risk factor - targeting senescence  
**Jan Van Deursen, USA**



### Tuesday October 6

Understanding biology for clinical application

The lipoprotein(a) story - from risk factor to causality to clinical trials  
**Sotirios Tsimikas, USA**

Immune modulation in atherosclerosis  
**Ziad Mallat, UK**

Prevention of cardiovascular diseases by glucose lowering drugs  
**Stefano del Prato, Italy**

Taming the gut microbiota  
**Stanley Hazen, USA**



### Wednesday October 7

The changing landscape in atherosclerotic vascular disease – Brave new world

Implementing systems biology to personalise medicine  
**Johan Björkegren, Sweden**

AI in CVD & beyond  
**Jörg Menche, Austria**

Personalised medicine in the elderly – how to avoid overtreatment  
**Heike Bischoff-Ferrari, Switzerland**

New therapeutic approaches  
**John Kastelein, The Netherlands**



## WORKSHOP TOPICS

### Advanced clinical seminars

- What is the best practice in secondary prevention in 2020?
- Risk prediction in primary prevention
- Management of non-lipid-risk factors
- NAFLD – natural history and emerging clinical trials

### Metabolism of lipids and lipoproteins

- Regulation and transport of sterols
- Cellular lipid trafficking
- Metabolic control of fat storage and combustion
- Lipoprotein receptors and transporters

### Pathogenesis of atherosclerosis

- Lipoproteins in the arterial wall
- Immune cells in the arterial wall
- Plaque rupture and erosion
- Epigenetics and non-coding RNA

### GUIDELINES SESSION

Deep dive into 2019 EAS/ESC dyslipidemia guidelines

### Prevention and treatment of CVD

- Controversies in nutrition
- Lipid-lowering therapies from childhood to old age
- Who are the highest risk patients and how do we manage them?
- Strategies towards personalised risk stratification



## KEYNOTE SPEAKER: Prof. Gökhan S. Hotamışlıgil, USA

Foundations of immunometabolism and implications for metabolic health and disease  
Monday October 5